Last reviewed · How we verify
monoclonal antibody Ch14.18
monoclonal antibody Ch14.18 is a Monoclonal antibody Biologic drug developed by National Cancer Institute (NCI). It is currently in Phase 3 development for Relapsed or refractory neuroblastoma. Also known as: Ch14.18, MOAB Ch14.18.
Ch14.18 is a monoclonal antibody that targets GD2, a disialoganglioside found on the surface of certain cancer cells.
Ch14.18 is a monoclonal antibody that targets GD2, a disialoganglioside found on the surface of certain cancer cells. Used for Relapsed or refractory neuroblastoma.
At a glance
| Generic name | monoclonal antibody Ch14.18 |
|---|---|
| Also known as | Ch14.18, MOAB Ch14.18 |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | Monoclonal antibody |
| Target | GD2 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ch14.18 works by binding to GD2, which helps the immune system recognize and attack cancer cells. This can lead to the destruction of cancer cells and the slowing of tumor growth.
Approved indications
- Relapsed or refractory neuroblastoma
Common side effects
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma (PHASE1)
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (PHASE1, PHASE2)
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (PHASE3)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (PHASE2)
- Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma (PHASE1)
- Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- monoclonal antibody Ch14.18 CI brief — competitive landscape report
- monoclonal antibody Ch14.18 updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about monoclonal antibody Ch14.18
What is monoclonal antibody Ch14.18?
How does monoclonal antibody Ch14.18 work?
What is monoclonal antibody Ch14.18 used for?
Who makes monoclonal antibody Ch14.18?
Is monoclonal antibody Ch14.18 also known as anything else?
What drug class is monoclonal antibody Ch14.18 in?
What development phase is monoclonal antibody Ch14.18 in?
What are the side effects of monoclonal antibody Ch14.18?
What does monoclonal antibody Ch14.18 target?
Related
- Drug class: All Monoclonal antibody drugs
- Target: All drugs targeting GD2
- Manufacturer: National Cancer Institute (NCI) — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory neuroblastoma
- Also known as: Ch14.18, MOAB Ch14.18
- Compare: monoclonal antibody Ch14.18 vs similar drugs
- Pricing: monoclonal antibody Ch14.18 cost, discount & access